Subscribe
img_1651
22 October 2019AmericasSarah Morgan

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN 19: choose your IP strategy wisely, warn IP experts
24 October 2019   Choosing the right IP strategy is crucial for companies, but constrained budgets and picking the wrong partners are all factors that can steer companies off the correct path.
Biotechnology
LSPN Connect: Protecting biologics at home and abroad
4 September 2020   Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
LSPN 19: choose your IP strategy wisely, warn IP experts
24 October 2019   Choosing the right IP strategy is crucial for companies, but constrained budgets and picking the wrong partners are all factors that can steer companies off the correct path.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Biotechnology
LSPN Connect: Protecting biologics at home and abroad
4 September 2020   Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern.

More on this story

Americas
LSPN 19: choose your IP strategy wisely, warn IP experts
24 October 2019   Choosing the right IP strategy is crucial for companies, but constrained budgets and picking the wrong partners are all factors that can steer companies off the correct path.
Americas
LSPN Connect: Challenges in the US patent landscape
21 September 2020   Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Biotechnology
LSPN Connect: Protecting biologics at home and abroad
4 September 2020   Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York